ATE543506T1 - Methode zur stabilisierung von proteinen - Google Patents
Methode zur stabilisierung von proteinenInfo
- Publication number
- ATE543506T1 ATE543506T1 AT05749282T AT05749282T ATE543506T1 AT E543506 T1 ATE543506 T1 AT E543506T1 AT 05749282 T AT05749282 T AT 05749282T AT 05749282 T AT05749282 T AT 05749282T AT E543506 T1 ATE543506 T1 AT E543506T1
- Authority
- AT
- Austria
- Prior art keywords
- bulk
- monomeric protein
- excipient
- stabilizing proteins
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04076627 | 2004-06-01 | ||
PCT/EP2005/052413 WO2005117948A1 (en) | 2004-06-01 | 2005-05-27 | Method of stabilizing proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE543506T1 true ATE543506T1 (de) | 2012-02-15 |
Family
ID=34928262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05749282T ATE543506T1 (de) | 2004-06-01 | 2005-05-27 | Methode zur stabilisierung von proteinen |
Country Status (17)
Country | Link |
---|---|
US (1) | US7858082B2 (de) |
EP (1) | EP1750750B1 (de) |
JP (1) | JP2008500995A (de) |
CN (1) | CN1993138B (de) |
AT (1) | ATE543506T1 (de) |
AU (1) | AU2005249232B2 (de) |
BR (1) | BRPI0510527A (de) |
CA (1) | CA2567309A1 (de) |
EA (1) | EA012281B1 (de) |
ES (1) | ES2381674T3 (de) |
HK (1) | HK1102561A1 (de) |
IL (1) | IL179617A0 (de) |
MX (1) | MXPA06014079A (de) |
NO (1) | NO20065861L (de) |
UA (1) | UA93349C2 (de) |
WO (1) | WO2005117948A1 (de) |
ZA (1) | ZA200610041B (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
TWI272948B (en) * | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
BRPI0413276B8 (pt) | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PL1969004T3 (pl) | 2005-12-28 | 2012-01-31 | Novo Nordisk As | Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
NZ571757A (en) * | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
CN101437823B (zh) | 2006-05-04 | 2014-12-10 | 勃林格殷格翰国际有限公司 | 多晶型 |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
JP5577249B2 (ja) * | 2007-08-24 | 2014-08-20 | ノボ ノルディスク ヘルス ケア アーゲー | 加熱処理による第vii因子ポリペプチド組成物中の二量体含有量の低減 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
ES2387236T3 (es) * | 2007-12-20 | 2012-09-18 | Merck Serono S.A. | Formulaciones de interferón beta pegilado |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
EP2403620B1 (de) | 2008-10-16 | 2016-04-06 | Scientek LLC | Verfahren und Vorrichtung zur Herstellung von Alkohol oder Zucker unter Verwendung eines grosstechnischen Bioreaktors |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
WO2010057259A1 (en) * | 2008-11-19 | 2010-05-27 | James Cook University | Protein stability assay using a fluorescent reporter of protein folding |
CA2745037C (en) | 2008-12-23 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
BR112012011403B8 (pt) | 2009-11-13 | 2021-05-25 | Sanofi Aventis Deutschland | composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma |
KR101972301B1 (ko) | 2009-11-13 | 2019-04-25 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
CA2809321C (en) | 2010-08-30 | 2018-08-14 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
CN103816115B (zh) * | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
KR101841527B1 (ko) | 2010-11-11 | 2018-03-23 | 애브비 바이오테크놀로지 리미티드 | 개선된 고농도 항-TNFα 항체 액체 제형 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
EP2731947B1 (de) | 2011-07-15 | 2019-01-16 | Boehringer Ingelheim International GmbH | Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes |
HUE027989T2 (en) | 2011-08-29 | 2016-11-28 | Sanofi Aventis Deutschland | A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (de) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
CN103271871A (zh) * | 2013-03-18 | 2013-09-04 | 长春海伯尔生物技术有限责任公司 | 一种重组人干扰素注射液及其制备方法 |
WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
EP3110449B1 (de) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medizinische verwendung eines dpp-4-inhibitors |
SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
JP7183268B2 (ja) * | 2017-11-20 | 2022-12-05 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
CA2275890C (en) * | 1996-12-24 | 2011-11-01 | Biogen, Inc. | Stable liquid interferon formulations |
US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
EP1426058A3 (de) * | 1997-09-23 | 2004-07-28 | Dr. Rentschler Biotechnologie GmbH | Flüssige Interferon-Beta Formulierungen |
SI1075281T1 (en) | 1998-04-28 | 2005-02-28 | Applied Research Systems Ars Holding N.V. | Polyol-ifn-beta conjugates |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
JP2004522803A (ja) * | 2001-06-29 | 2004-07-29 | マキシゲン・エイピーエス | インターフェロン製剤 |
JP5057648B2 (ja) * | 2002-09-26 | 2012-10-24 | 塩野義製薬株式会社 | 安定化されたタンパク組成物 |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
-
2005
- 2005-05-27 EA EA200602254A patent/EA012281B1/ru not_active IP Right Cessation
- 2005-05-27 ZA ZA200610041A patent/ZA200610041B/en unknown
- 2005-05-27 EP EP05749282A patent/EP1750750B1/de active Active
- 2005-05-27 MX MXPA06014079A patent/MXPA06014079A/es active IP Right Grant
- 2005-05-27 AT AT05749282T patent/ATE543506T1/de active
- 2005-05-27 ES ES05749282T patent/ES2381674T3/es active Active
- 2005-05-27 US US11/597,982 patent/US7858082B2/en not_active Expired - Fee Related
- 2005-05-27 UA UAA200612403A patent/UA93349C2/ru unknown
- 2005-05-27 BR BRPI0510527-7A patent/BRPI0510527A/pt not_active IP Right Cessation
- 2005-05-27 JP JP2007513937A patent/JP2008500995A/ja not_active Ceased
- 2005-05-27 CA CA002567309A patent/CA2567309A1/en not_active Withdrawn
- 2005-05-27 AU AU2005249232A patent/AU2005249232B2/en not_active Ceased
- 2005-05-27 CN CN2005800256604A patent/CN1993138B/zh not_active Expired - Fee Related
- 2005-05-27 WO PCT/EP2005/052413 patent/WO2005117948A1/en active Application Filing
-
2006
- 2006-11-27 IL IL179617A patent/IL179617A0/en unknown
- 2006-12-19 NO NO20065861A patent/NO20065861L/no not_active Application Discontinuation
-
2007
- 2007-10-04 HK HK07110814.6A patent/HK1102561A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
UA93349C2 (ru) | 2011-02-10 |
EA012281B1 (ru) | 2009-08-28 |
EP1750750A1 (de) | 2007-02-14 |
WO2005117948A1 (en) | 2005-12-15 |
CN1993138B (zh) | 2010-12-15 |
AU2005249232B2 (en) | 2010-08-05 |
EA200602254A1 (ru) | 2007-06-29 |
MXPA06014079A (es) | 2007-02-15 |
JP2008500995A (ja) | 2008-01-17 |
CA2567309A1 (en) | 2005-12-15 |
BRPI0510527A (pt) | 2007-10-30 |
AU2005249232A1 (en) | 2005-12-15 |
US20070244299A1 (en) | 2007-10-18 |
HK1102561A1 (en) | 2007-11-30 |
ZA200610041B (en) | 2008-07-30 |
EP1750750B1 (de) | 2012-02-01 |
IL179617A0 (en) | 2007-05-15 |
US7858082B2 (en) | 2010-12-28 |
ES2381674T3 (es) | 2012-05-30 |
CN1993138A (zh) | 2007-07-04 |
NO20065861L (no) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE543506T1 (de) | Methode zur stabilisierung von proteinen | |
EA200602257A1 (ru) | Стабилизированные жидкие препаративные формы интерферона | |
EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
NO2017027I2 (no) | efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
DE60144145D1 (de) | Subtilisin-variante | |
ATE517119T1 (de) | Einzelketteninsulin | |
BRPI0514340A (pt) | formulações de estabilização | |
DK1748701T3 (da) | Fremgangsmåder og sammensætninger involverende valleproteinisolater | |
ECSP066495A (es) | Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) | |
DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
EA200800327A1 (ru) | Стабилизированные жидкие композиции интерферона, не содержащие человеческий сыворотный альбумин | |
FR2857267B1 (fr) | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. | |
DK1276763T3 (da) | Anti-fryseproteiner, deres fremstilling og anvendelse | |
DE60235985D1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
EA200800205A1 (ru) | Кальций-пептидный компонент | |
IL173954A0 (en) | Libraries of recombinant chimeric proteins and methods of generating the same | |
WO2008068428A3 (fr) | Utilisation cosmétique de protéines de type chitinase | |
ATE506433T1 (de) | Prozessierung von peptiden und proteinen | |
DE60015559D1 (de) | Sentrin-spezifische menschliche protease senp1 | |
ATE468753T1 (de) | Molkenproteinhydrolysate | |
WO2005099745A3 (en) | Gcp-170 fusion proteins and uses thereof | |
ATE427355T1 (de) | Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna | |
ATE392480T1 (de) | Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen | |
ATE450546T1 (de) | Impfstoffe mit ornithobakterium rhinotracheale- untereinheit |